Allogene Therapeutics (ALLO) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 49.0% versus a loss of 55.6%. Over five years, LCTX leads with a -61.2% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $195.3 million), about 1.1 times the size, while Lineage Cell Therapeutics is growing revenue faster (+53.2% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | LCTX |
|---|---|---|
| Share price | $0.6277 | $0.7719 |
| Market cap | $217.48M | $195.26M |
| 1-day change | -5.88% | -5.87% |
| YTD return | -54.18% | -53.78% |
| 1-year return | -48.97% | -55.64% |
| 5-year return | -96.51% | -61.21% |
| EPS (TTM) | $-0.61 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $14.56M |
| Revenue growth (YoY) | -100.00% | +53.24% |
| Net income (latest FY) | $-190.89M | $-63.53M |
| Operating margin | — | -251.57% |
| Net margin | — | -436.47% |
| 52-week high | $4.46 | $1.99 |
| 52-week low | $0.6192 | $0.77 |
| Distance from 52-week high | -85.93% | -61.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +612.53% |
| Average volume | 7.69M | 1.64M |
| Shares outstanding | 346.47M | 252.95M |
| Employees | 150 | 72 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lineage Cell Therapeutics grew revenue faster in its latest fiscal year (+53.24% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
ALLO vs LCTX FAQ
Which is bigger, Allogene Therapeutics or Lineage Cell Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $195.26M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, ALLO or LCTX?
ALLO returned -48.97% over the past 12 months, compared with -55.64% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Lineage Cell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.